Canaccord Maintains Buy Rating on Biogen, Raises Target to $272
Canaccord Genuity maintained its Buy rating on Biogen and raised its price target to $272 from $248.
Related stories
Reddit Shares Tumble More Than 25% After Search Traffic Warning
Reddit shares fell more than 25% Friday morning after a warning about search traffic and user volume in the months ahead. Third-quarter revenue rose more than 50%, but Reddit misse
M impact | EQUITY | Oct 30, 2026, 02:44 PM UTC
ExxonMobil CEO Says Company Intends to Grow Natural Gas Portfolio
M impact | EQUITY | Oct 30, 2026, 02:40 PM UTC
S&P/TSX Composite Falls 1.6% as Base Metals Shares Drop
The S&P/TSX fell 1.6% mid-morning Friday as base metals shares declined.
M impact | EQUITY | Oct 30, 2026, 02:34 PM UTC
Colgate-Palmolive Raises Full-Year Earnings Growth Outlook
Colgate-Palmolive raised its full-year earnings growth outlook after a third-quarter beat.
M impact | EQUITY | Oct 30, 2026, 02:34 PM UTC
US session market picture: S&P 500 -1.54%, Nasdaq 100 -3.03%; EUR/USD -0.3%, WTI +2.25%, WBD leads volume
US session market picture. US index futures: S and P futures is down 1.54 percent, Nasdaq futures is down 3.03 percent, Dow futures is down 0.74 percent and Russell futures is down
M impact | EQUITY | Oct 30, 2026, 02:31 PM UTC
AIG Agrees to Acquire Everest’s Chile Insurance Operations, Completes Colombia Deal
AIG announced an agreement to acquire Everest’s insurance operations in Chile and said it completed its acquisition of Everest’s Colombia operations.
M impact | EQUITY | Oct 30, 2026, 02:30 PM UTC